Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!
$2.31
-0.0100 (-0.431%)
At Close: May 09, 2024
Forecast Earnings Dividends Fundamentals Insider Trading Signals Historical Prices Predictions News Profile

Range Low Price High Price Comment
30 days $1.31 $4.00 Thursday, 9th May 2024 CYCC stock ended at $2.31. This is 0.431% less than the trading day before Wednesday, 8th May 2024. During the day the stock fluctuated 14.48% from a day low at $2.27 to a day high of $2.60.
90 days $1.31 $4.00
52 weeks $1.31 $13.20

Historical Cyclacel Pharmaceuticals prices

Date Open High Low Close Volume
Mar 09, 2020 $0.510 $0.510 $0.480 $0.480 111 775
Mar 06, 2020 $0.540 $0.540 $0.510 $0.514 46 906
Mar 05, 2020 $0.560 $0.562 $0.540 $0.540 55 269
Mar 04, 2020 $0.570 $0.570 $0.535 $0.560 47 500
Mar 03, 2020 $0.540 $0.578 $0.520 $0.555 43 958
Mar 02, 2020 $0.530 $0.578 $0.510 $0.542 79 622
Feb 28, 2020 $0.520 $0.550 $0.515 $0.530 93 811
Feb 27, 2020 $0.560 $0.582 $0.511 $0.543 213 887
Feb 26, 2020 $0.651 $0.670 $0.576 $0.612 194 495
Feb 25, 2020 $0.687 $0.690 $0.670 $0.670 63 839
Feb 24, 2020 $0.700 $0.716 $0.680 $0.697 58 851
Feb 21, 2020 $0.698 $0.720 $0.680 $0.711 107 129
Feb 20, 2020 $0.710 $0.735 $0.680 $0.684 150 435
Feb 19, 2020 $0.720 $0.735 $0.710 $0.730 44 410
Feb 18, 2020 $0.720 $0.732 $0.710 $0.714 46 844
Feb 14, 2020 $0.740 $0.750 $0.720 $0.740 49 738
Feb 13, 2020 $0.730 $0.740 $0.720 $0.740 76 350
Feb 12, 2020 $0.723 $0.740 $0.710 $0.740 64 804
Feb 11, 2020 $0.704 $0.720 $0.690 $0.720 48 812
Feb 10, 2020 $0.750 $0.750 $0.680 $0.700 88 511
Feb 07, 2020 $0.742 $0.750 $0.710 $0.719 66 847
Feb 06, 2020 $0.700 $0.730 $0.700 $0.718 50 237
Feb 05, 2020 $0.740 $0.760 $0.700 $0.715 131 279
Feb 04, 2020 $0.666 $0.730 $0.661 $0.725 135 162
Feb 03, 2020 $0.680 $0.700 $0.655 $0.660 114 723
Click to get the best stock tips daily for free!

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-... CYCC Profile

Golden Star

Ticker Date Change Price
PAG May 07 1.87% $153.22
WMT May 06 0.95% $59.87
UNP May 06 3.09% $239.21
JPM May 06 2.86% $192.00
ASH May 03 2.10% $95.85
INVH May 03 1.72% $34.39
INGR May 03 4.72% $114.56
VCSH May 03 0.0260% $76.93
BNDX May 03 0.205% $48.68
BBCA May 03 1.93% $65.44
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT